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ABSTRACT
Background: Alcohol consumption, current injecting drug use, and pre-existing men-
tal illness have been identified as 3 of the main reasons for excluding patients from 
treatment for hepatitis C.
Objectives: We reviewed the literature to obtain an evidence base for these common 
exclusion criteria.
Materials and Methods: We reviewed original research and meta-analyses investigating 
the effects of alcohol consumption, current injecting drug use, and pre-existing men-
tal illness.
Results: We identified 66 study reports relevant to the review, but found only limited 
evidence to support withholding of treatment on the basis of the 3 previously men-
tioned exclusion criteria.
Conclusions: Currently, there is a lack of evidence for many of the barriers faced by pa-
tients in availing treatment for hepatitis C. Adherence to treatment routine was found 
to be a better predictor of sustained virological response than injecting drug or alco-
hol consumption during treatment period or the presence of a pre-existing mental 
disorder. Although several challenges remain, we need to ensure that treatment deci-
sions are based on the best available evidence and the treatment is performed appro-
priately on a case-by-case basis.
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1. Background
In developed countries, people who inject drugs (PWID) 
are at the greatest risk of infection with hepatitis C virus 
(HCV) (1, 2). Despite the lack of evidence, throughout the 
1990s, regulations restricting PWIDs’ access to referral 
for specialist treatment for their chronic HCV infection 
has  existed  in  a  number  of  western  countries  (3,  4). 
The  2005  special  issue  (40,  supplement  5)  of  Clinical 
Infectious  Diseases  was  dedicated  to  HCV  infection, 
managing opiate dependence, and developing models 
of integrated care for HCV-positive people. The summary 
in  the  special  issue  concluded  that  there  remained 
important  knowledge  gaps  on  the  providing  the  best 
health-care and treatment for HCV infection in current 
injecting  drug  users  and  stated  that  further  research Hepat Mon. 2011;11(7):513-518
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would be required to specifically address this issue (5).
A recent review on HCV treatment for PWID in patient 
groups  with  and  without  a  history  of  injecting  drug 
use showed that the group with a history of injecting 
drug use was able to successfully complete treatment 
with  minor  variations  in  treatment  outcomes  (6). 
Presently,  a  number  of  international  research  studies 
conducted  in  different  treatment  settings  show  that 
it is possible to successfully provide HCV treatment to 
current  injectors  (7-10).  Previous  research  has  shown 
that there are individual (both the patient and provider) 
and structural barriers to HCV treatment (11-13). During 
a  previous  literature  review  on  hepatitis  C  antiviral   
treatment in PWID, we identified 3 barriers that may on 
an individual level, affect the treatment in injecting drug 
users and were commonly cited as the formal exclusion 
criteria for, or predictors of exclusion from, the antiviral 
therapy: continued injecting drug use, alcohol use, and 
pre-existing mental disorders (11, 14-21). 
2. Objectives
Although  we  observed  that  individual  barriers  were 
not the only ones that prevented injecting drug users 
from  accessing  treatment,  we  limited  our  review  on 
this to focus more on the above-mentioned 3 barriers. 
For  each  barrier,  we  delineated  a  myth  that  underlay 
the  exclusion  of  affected  HCV-positive  patients  from 
receiving treatment. In the context of our study, a myth 
was defined as a commonly held belief that may or may 
not have been consistent with the available evidence.
3. Materials and Methods
A  literature  review  was  undertaken  on  the  effects  of 
alcohol  consumption,  mental  disorder,  and  current 
injecting drug use on hepatitis C antiviral treatment to 
evaluate the extent to which the 3 myths were evidence-
based.  The  literature  searches  were  conducted  from 
2008 to July 2010. By using Ovid MEDLINE®, we searched 
the  entries  in  the  database  from  1996  to  the  present 
with daily update, and keyword mapping identified the 
following subject headings to be used as search terms: 
“hepatitis C”, “hepacvirus”, “antiviral agents”, “alcohol-
related disorders”, “alcohol drinking”, “mood disorders”, 
and “substance use, intravenous”. Various combinations 
and  sub-categories  of  the  above  subject  headings 
were used in the searchers. We also used the “explode” 
function in Medline, which allows broad searching of 
a  term  while  simultaneously  narrowing  the  searches 
for  all  other  terms  in  the  subject  heading.  Reference 
lists  in  the  identified  articles  were  also  searched  for 
obtaining  any  relevant  information.  We  included 
articles in English that described results from original 
research or meta-analyses that measure the outcomes of 
continuous alcohol consumption, a pre-existing mental 
illness,  and/or  current  injecting  drug  use  in  patients 
receiving  hepatitis  C  antiviral  therapy,  or  articles  that 
reported a successful follow-up for measuring the rates 
of reinfection of patients who received antiviral therapy.
4. Results
Over 400 articles were filtered through the database 
searches, and 66 were included in this review. In the next 
section of the paper, we include a critical review of the 3 
myths identified.
4.1. Myth 1: Illicit use of drugs during HCV treatment 
may cause complications and increase the chance of 
reinfection
Few  studies,  all  with  small  samples  (N  <  75),  have 
investigated the impact that current injecting drug use 
during  HCV  treatment  has  on  the  rates  of  sustained 
virological  response  (SVR).  Four  studies  have  found 
similar  SVR  rates  among  participants  who  reported 
injecting drug during the treatment period and those 
who had a history of injecting use but had reported no 
drug use during the treatment (8, 10, 22, 23). Participants 
of 2 studies who injected regularly (at least once in every 
2  days  for  a  prolonged  period  during  the  treatment) 
were observed to have lower SVR rates than those who 
abstained  from  injecting  or  injected  less  frequently 
during the treatment, even though the differences did 
not reach a statistically significant value (22, 23).
Several studies have found that those who continued 
injecting  drug  use  during  treatment  were  less  likely 
to  comply  with  the  treatment  regimen  and  hence 
did not complete treatment (24, 25). However, 2 other 
studies showed that frequent injecting drug use during 
treatment did not affect the probability of attaining an 
SVR as long as the treatment regimen was completed (8, 
26). Few studies have conducted a systematic follow-up of 
the participants after HCV treatment, and those studies 
have shown low rates of reinfection (27). Although there 
are cases of posttreatment reinfection in the literature 
(28-30), the incidence of such cases is less frequent than 
the incidence of HCV infection (31) or reinfection (32, 33) 
in community-based studies.
4.1.1. Implications
Adherence  to  treatment  appears  to  be  a  stronger 
predictor of whether injectors with chronic HCV infection 
will achieve SVR than whether or at what levels they inject 
drugs during the treatment period. The less clear part is 
how the complex social and environmental factors can be 
managed so that individuals could have strategies that 
can help ensure adherence to the treatment regimen. 
This includes management of side effects that may occur 
during treatment. Although follow-up after treatment to 
measure the reinfection rates have been done in a lesser 
number of participants, to date the reinfection rates that 
have been observed after treatment are far lower than 
those observed after spontaneous clearance. Therefore, Hepat Mon. 2011;11(7):513-518
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there  is  no  evidence  showing  that  the  potential  for 
posttreatment HCV reinfection is a sound reason for not 
offering treatment to PWID.
4.2. Myth 2: Alcohol consumption before and/or during 
treatment  has  major  implications  for  the  successful 
treatment of HCV
The  biological  mechanisms  by  which  alcohol  might 
affect  HCV  treatment  outcomes  have  been  researched 
(34-37). Alcohol consumption has been found to increase 
the likelihood of histological steatosis and to accelerate 
hepatic fibrosis and inflammation in patients with HCV 
infection (38-42). Some studies have found that alcohol 
consumption  raises  the  HCV  viral  load  (41);  however, 
a  meta-analysis  of  the  effect  of  alcohol  consumption 
on  HCV  replication  failed  to  show  any  association 
between alcohol consumption and HCV viral load (38). 
Some  studies  have  reported  that  a  history  of  alcohol 
consumption  has  an  adverse  effect  on  HCV  treatment 
outcomes by reducing the probability of attaining SVR 
(43-46).  An  earlier  study  had  reported  a  weak  dose–
response relationship between the quantity of alcohol 
ever consumed and the likelihood of failing treatment 
(45). However, other studies have reported that the weak 
dose–response  effect  can  be  reversed  by  observing  a 
lengthy period of pretreatment abstinence from alcohol 
consumption (47, 48). Some other studies have found an 
association between pretreatment alcohol consumption 
and treatment outcome; however, a univariate analysis 
performed  after  adjusting  for  other  factors  in  these 
studies failed to establish any such association (41).
The  effect  of  alcohol  consumption  during  treatment 
independent  of  the  effect  of  a  history  of  alcohol 
consumption,  on  treatment  efficacy  remains  unclear. 
Some  studies  have  shown  that  alcohol  consumption 
during treatment has a negative impact on the treatment 
outcome  moreover,  a  dose–response  effect  has  been 
observed  during  a  univariate  analysis  performed  in  1 
study (41). However, some other studies have reported 
successful treatment outcomes among patients who have 
continued to consume moderate amounts of alcohol (up 
to 24 grams per day) during treatment (49, 50). A study 
in Canada found that participants who had consumed 
alcohol 6 months prior to treatment were less likely to 
complete the treatment regimen and were less likely to 
attain an SVR; however, even in this study, no association 
could  be  found  between  alcohol  consumption  during 
treatment and the treatment outcomes (51). Therefore, in 
studies where alcohol consumption has been associated 
with  a  decrease  in  SVR,  it  is  unclear  if  the  effect  was 
due to alcohol consumption or a reduced adherence to 
treatment (40, 49). Indeed, in a treatment study in which 
continuous  alcohol  consumption  was  considered  an 
exclusion  criteria  for  receiving  treatment,  consuming 
an average of more than 3 alcoholic drink per day within 
a year prior to treatment was an independent predictor 
of  early  treatment  discontinuation  after  adjusting 
for  factors  of  race,  illicit  substance  use,  and  income; 
however, alcohol consumption itself was not associated 
with attaining an SVR (52).
Overall,  we  found  that  many  of  the  studies  on  the 
effect of alcohol on treatment response did not admit 
heavy drinkers into treatment; therefore, we could only 
examine  the  effects  of  prior  alcohol  consumption  on 
the  treatment  outcome  (42,  43,  46-48).  Among  those 
studies that did investigate alcohol consumption during 
treatment,  the  participant  numbers  were  small,  and 
many studies were on interferon monotherapy, which is 
a relatively ineffective treatment regimen compared to 
the latest treatment regimens, and most do not account 
for potential ambiguity in the outcome (41, 45, 51).
4.2.1. Implications
Until  further  studies  can  establish  the  direct  effect 
of  alcohol  consumption  on  treatment  success,  while 
adjusting  for  adherence  to  HCV  treatment,  it  seems 
reasonable to advise patients to decrease their level of 
alcohol consumption before and during HCV treatment. 
However,  given  that  some  patients  have  successfully 
completed treatment without abstaining from alcohol 
consumption, a patient’s inability to abstain from alcohol 
consumption before and during therapy should not be 
seen as an automatic exclusion criterion for receiving 
HCV treatment.
4.3. Myth 3: Pre-existing mental health problems among 
PWID lead to HCV treatment being unviable
Depression is one of the most common side-effects of 
HCV treatment (53); a review reported that up to 40% 
of the people being treated with interferon experience 
a  mild  to  moderate  depression  (54).  Several  studies 
have investigated the relationship between depression 
(judging  by  either  a  history  of  depression  or  a 
depression score when commencing the treatment) and 
treatment outcomes. All studies except 1 have observed 
no  significant  relationship  between  depression  and 
treatment adherence (55), treatment completion (55-57), 
early or end of treatment response (55, 58), or SVR (56). 
A larger study found that patients with depression were 
significantly less likely to complete treatment; however, 
there was no significant difference in SVR (59). One study 
examined the difference in treatment outcomes between 
patients  with  and  without  schizophrenia  and  found 
no  difference  in  the  treatment  completion  or  end-of-
treatment response, but the patients with schizophrenia 
were significantly more likely to achieve an SVR (60).
Other  studies  have  involved  a  combined  analysis 
of  various  psychiatric  disorders  on  the  treatment 
outcomes. One study found no difference in treatment 
completion among patients with current or past mood 
or anxiety disorders (61). Two studies found no difference 
in treatment completion, end-of-treatment response, or 
SVR among patients with a current or past psychiatric Hepat Mon. 2011;11(7):513-518
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disorder and those without (62, 63). One study found no 
difference in end of treatment response or SVR between 
patients with a history of mental health issues and/or 
drug use and those patients without (64)
Notably,  8  of  10  studies  listed  above  involved  fewer 
than 100 individuals, and many studies did not perform 
multivariate  analysis  (56,  58-64),  were  conducted 
retrospectively  (56,  60,  63,  64),  and/or  had  various 
exclusion criteria relating to ongoing or uncontrolled 
psychiatric illness (58, 59, 63, 64). Multiple studies have 
found  an  association  between  a  lifetime  history  of 
depression, or high depression scores at baseline, and 
development of depression during HCV treatment (57, 59, 
64-67). One study found no difference in the symptoms of 
depression, schizophrenia, or mania between those with 
and without schizophrenia at baseline (68). Similarly, no 
difference was found in the development of symptoms 
during treatment when a group of patients with various 
psychiatric disorders was compared to a group of patients 
without any psychiatric disorders (69) or when a group 
of patients with a history of psychiatric disorders and/
or illicit drug use was compared to a group of patients 
without any of these (63). However, similar to the studies 
investigating  the  relationship  between  pre-existing 
mental health problems and treatment outcomes, 8 of 
11  studies  involved  fewer  than  100  participants,  and  2 
studies were conducted retrospectively (60, 64).
4.3.1. Implications
Although, there is some evidence to suggest that having 
a history of depression or a high depression score when 
commencing treatment increases the likelihood of an 
individual developing depression during HCV treatment 
and  potentially  affecting  treatment  completion,  there 
is no evidence to suggest that a pre-existing psychiatric 
disorder  could  adversely  affect  the  likelihood  of 
attaining an end-of-treatment response or SVR. Evidence 
also suggests that people experience a number of side 
effects from their HCV treatment. These results suggest 
that  rather  than  automatically  excluding  individuals 
with pre-existing psychiatric disorders from treatment, 
they should receive appropriate care for their psychiatric 
disorder before, during, and after HCV treatment.
5. Conclusion
In  most  developing  countries,  formal  policies 
restricting  PWID  from  accessing  HCV  treatment  have 
been lifted over the past 10 years. Although some PWID 
now  receive  treatment,  the  rates  remain  low;  many 
PWID are still being excluded from treatment because of 
concerns about their continuous alcohol consumption, 
injecting drug use, and pre-existing mental illness. Our 
review highlights the lack of evidence supporting these 
exclusions. Many of the studies that we reviewed included 
only a small number of participants and failed to adjust 
their findings to account for potential ambiguity. Our 
evidence suggests that a patient’s likelihood of attaining 
SVR  is  impacted  more  by  the  adherence  to  treatment 
than  by  the  frequency  of  drug  injecting  during  the 
treatment period. Likewise, although there is evidences 
showing that a pre-existing mental illness may increase 
the likelihood of experiencing depression as a side effect 
of the treatment, from our review, it appears that the 
patients with pre-existing mental illnesses who complete 
the treatment are just as likely as other patients to attain 
SVR; this highlights the role of concurrent management 
of mental health problems with HCV treatment.
To ensure that alcohol consumption does not have a 
direct effect on treatment efficacy, continued counseling 
should be offered to patients on reducing their alcohol 
consumption before and during treatment. However, as 
some  patients  have  successfully  completed  treatment 
even while continuing to consume moderate amounts 
of alcohol, alcohol consumption should not be seen as 
an automatic exclusion criterion for HCV treatment. The 
decision  to  treat  HCV  should  be  patient  centered  and 
made on a case-by-case basis with foremost attention to 
the needs and interests of the person seeking treatment. 
The research in this area is ongoing, and as the number 
of studies increases, we will be able to pool more data on 
a range of indicators, which may help understand the 
factor that has the greatest impact on the HCV treatment 
outcome. At present, there is no compelling evidence for 
restricting access to PWID seeking HCV treatment. We 
consider this the right time for making evidence-based 
decisions rather than making decisions based on pre-
conceived ideas about patients who deserve treatment 
for HCV, and we hope that those involved in deciding to 
offer HCV treatment would consider the results of our 
study.
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